Figure 3From: Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]Kaplan-Meier survival curves. The PRISM program was used to construct the curves for the placebo and M-FP immunized patients. M-FP, oxidized mannan conjugated to MUC1 fusion protein.Back to article page